Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex322a13a4c.htm |
| EX-32.1 - EX-32.1 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex321c69c19.htm |
| EX-31.2 - EX-31.2 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex312bf0888.htm |
| EX-31.1 - EX-31.1 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex311433cb7.htm |
| EX-21.1 - EX-21.1 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex211ece4e8.htm |
| EX-4.18 - EX-4.18 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex418efc004.htm |
| 10-K - 10-K - Timber Pharmaceuticals, Inc. | bpmx-20200131x10k.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-227262, 333-217419, 333-213627 and 333-201708), the Registration Statements on Form S-3 (Nos. 333-229459, 333-220012, 333-213635 and 333-212015) and the Registration Statements on Form S-1 (Nos. 333-221686 and 333-221027) of BioPharmX Corporation of our report (which contains an explanatory paragraph relating to BioPharmX Corporation’s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) dated March 23, 2020 relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.
/s/ BPM LLP
San Jose, California
March 23, 2020